Svendsen 1992.

Methods	Setting: Denmark, hospital outpatient clinic Length of intervention: 6 weeks Design: crossover, no washout Randomised: yes, method not stated Allocation concealment: unclear Masking: double‐blind Excluded: not stated Withdrawals: stated Baseline characteristics: comparable Jadad score: 3
Participants	39 adults Age range: 18 years or older Inclusion criteria: Asthma poorly controlled with inhaled steroids, daily dose 300 ‐ 500 mcg/day FEV1, FVC or PEFR < 70% predicted 15% or greater improvement in FEV1 after inhaled beta2 agonist Bronchial hyper‐responsiveness to histamine (PC20 FEV1 2 mg/ml or less) Exclusion criteria: Regular oral steroids during 3 months prior to the trial Unable to use aerosols correctly Pregnancy or significant co‐existent disease Respiratory infections within last 4 weeks
Interventions	BDP: 250 mcg 3 puffs 2xdaily (1500 mcg/day) via MDI and placebo via MDI+Inhalet spacer BUD: 200 mcg 4 puffs 2xdaily (1600 mcg) via MDI+Inhalet spacer and placebo via MDI
Outcomes	FEV1 FVC Morning PEFR Evening PEFR Clinic PEFR Histamine BHR (PC20 FEV1) Sleep disturbance, wheeze and activity restriction score Rescue beta2 agonist use (puffs/day) Plasma cortisol (time not stated) Plasma cortisol 30 min post 250 mcg iv tetracosactrin
Notes	Reply from author but unable clarify details of randomisation procedure Not stated if carryover effects were tested for.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear